About this trial
This observational study comprises consecutively patients with cerebrovascular diseases admitted to the Stroke Unit at Akershus University Hospital in Norway. Akershus University Hospital is the largest emergency care hospital in Norway and has a catchment area covering a population of 550.000, which is approximately 10 % of the Norwegian population and reasonably representative according to data from Statistics Norway. The hospital is public and serving both as a primary hospital and a university hospital. Due to the Norwegian, national, all-covering health-insurance, all patients enter the hospital and are considered for further in-patient care on the same conditions. The hospital has a stroke unit classified as a comprehensive stroke center according to European Stroke Organisation standards. Acute stroke management follows national and international guidelines. Overall, the ASIST-1 study will investigate management, outcome and prognosis of stroke and stroke care pathways and later follow up in primary care using several approaches combining existing clinical data from a representative population with different Norwegian health registries. Parts of the study are retrospective with prospective follow-up by health registries and parts of the study are prospective.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Cerebrovascular diseases (acute ischemic stroke, intracerebral hemorrhage, transient ischemic attack) or stroke mimics
Disqualifiers
None
Trial population
1. IVT treated patients 2012-2025 (2012-2018 retrospective, 2019-2025 prospective) 2. All patients with ICH (2011-2019 retrospective, 2020-2025 prospective) 3. All patients with acute ischemic stroke or ICH (2015-2018 retrospective, 2019-2025 prospective) 4. All patients admitted to the stroke care pathway (stroke/mimics 2015-2017) 5. All stroke patients treated with endovascular treatment 2012-2025 (2012-2018 retrospective, 2019-2025 prospective) 6. All patients with cerebellar hematoma 2008-2022 (retrospective) Data will be linked with data from general practitioners, Municipal Patient Registry (KRP/KUHR), Norwegian Patient Registry (NPR), Norwegian Prescription Database (NorPD), Norwegian Stroke registry, Cause of Death Registry (DÅR)
Trial design
Cohort
Other
Treatments tested in this trial
Not listed
Trial groups
6
Trial groupsSee each trial group below.
Trial outcomes
Primary outcomes
Large vessel occlusion in a representative Norwegian population
Incidence of large vessel occlusion 2015-2017
Functional status
modified Rankin Scale (mRS) 0-6 (0 normal, 6 dead) for all groups
Functional status
modified Rankin Scale (mRS) 0-6 (0 normal, 6 dead) for all groups
Mortality
Number dead vs total number of cases all groups
Secondary outcomes
Reasons for not giving thrombolysis in patients with acute stroke symptoms < 4.5 hours
Number of cases treated with thrombolysis vs number of cases evaluated in the acute stroke care pathway
Functional outcome of patients in the stroke fast track treated or not treated with thrombolysis (or endovascular thrombectomy),
Modified Rankin Scale (mRS) 0-6 (0 normal, 6 dead)
Mortality of patients in the stroke fast track treated or not treated with thrombolysis (or endovascular thrombectomy),
Mortality
Functional outcome after 1 year of patients in the stroke fast track treated or not treated with thrombolysis (or endovascular thrombectomy),
modified Rankin Scale (mRS) 0-6 (0 normal, 6 dead)
Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital, Akershus
Lead sponsor
University of Oslo
Collaborator
Oslo University Hospital
Collaborator